What Is the Amino-Acid Sequence of BPC-157?

What Is the Amino-Acid Sequence of BPC-157?

The amino-acid sequence commonly reported for BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. In standard one-letter amino-acid notation, it is GEPPPGKPADDAGLV. The sequence contains 15 residues, which is why BPC-157 is described as a pentadecapeptide.

Sequence identity is one of the foundational characteristics covered in BPC-157 Research: Identity, Formulation, Evidence, and Research Interpretation. Knowing the sequence helps define the peptide, but it does not establish the identity, purity, formulation, concentration, or quality of a particular sample bearing the BPC-157 label.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

The BPC-157 Sequence

The sequence is:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

In one-letter notation:

GEPPPGKPADDAGLV

The residues are written from the amino terminus toward the carboxyl terminus.

How Many Amino Acids Does BPC-157 Contain?

BPC-157 contains 15 amino-acid residues.

The positions are:

  • 1: Glycine
  • 2: Glutamic acid
  • 3: Proline
  • 4: Proline
  • 5: Proline
  • 6: Glycine
  • 7: Lysine
  • 8: Proline
  • 9: Alanine
  • 10: Aspartic acid
  • 11: Aspartic acid
  • 12: Alanine
  • 13: Glycine
  • 14: Leucine
  • 15: Valine

Residue numbering is useful when describing sequence-specific analytical observations or modifications.

One-Letter Amino-Acid Notation

One-letter notation compresses each amino acid into a single character.

For BPC-157:

  • G = glycine
  • E = glutamic acid
  • P = proline
  • K = lysine
  • A = alanine
  • D = aspartic acid
  • L = leucine
  • V = valine

This notation is useful for database searches, sequence comparison, and laboratory documentation.

Three-Letter Notation

The same sequence may be written using three-letter residue abbreviations:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

One-letter and three-letter representations describe the same residue order when terminal chemistry and stereochemistry are otherwise unchanged.

Why Residue Order Matters

A peptide sequence is defined not only by which amino acids are present but also by their order.

Rearranging the same 15 residues would create a different peptide.

Sequence order can influence:

  • conformation
  • charge distribution
  • enzyme recognition
  • chromatographic behavior
  • mass-spectrometric fragmentation
  • interaction with experimental systems

Peptide Bonds Connect the Residues

Adjacent amino-acid residues are connected through peptide bonds.

The chain progresses from:

  • the amino terminus
  • through the internal residues
  • to the carboxyl terminus

The sequence notation records this directional order.

The Amino Terminus

The first residue in the commonly reported sequence is glycine.

The reference form is commonly represented with a free amino terminus.

If the amino terminus were chemically modified, that change would need to be documented because it would represent a distinguishable molecular form.

The Carboxyl Terminus

The final residue is valine.

The reference sequence is commonly represented with a free carboxyl terminus.

A carboxyl-terminal modification such as amidation would alter the molecular composition and should not be assumed from the BPC-157 name.

Glycine Residues

Glycine appears at positions:

  • 1
  • 6
  • 13

Glycine has no carbon-containing side chain beyond hydrogen, giving it structural characteristics different from the other residues in the sequence.

Glutamic Acid

Glutamic acid appears at position 2.

Its side chain contains a carboxylic-acid group that can contribute to the charge properties of the peptide depending on environmental conditions.

This is a chemical characteristic rather than evidence of a biological effect.

The Proline-Rich Region

Proline appears at positions 3, 4, 5, and 8.

Three consecutive proline residues occur near the amino-terminal portion:

PPP

Proline has a cyclic side-chain structure that restricts backbone geometry relative to many other amino acids.

Why Proline Is Structurally Distinctive

Proline's side chain connects back to the backbone nitrogen.

In peptide-structure research, this can influence:

  • backbone flexibility
  • local conformation
  • cis-trans peptide-bond behavior
  • protease recognition

The actual conformation of a peptide still depends on its complete sequence and experimental environment.

Lysine

Lysine occurs at position 7.

Lysine contains a basic side-chain amino group.

This feature can contribute to:

  • charge behavior
  • chromatographic retention
  • ionization during mass spectrometry
  • chemical derivatization

These are analytical and structural considerations.

Alanine

Alanine occurs at positions 9 and 12.

Its relatively small hydrocarbon side chain contributes to the overall composition of the peptide.

Aspartic Acid

Aspartic acid appears at positions 10 and 11.

The sequence therefore contains the adjacent pair:

DD

Aspartic-acid side chains can influence charge and selected degradation pathways depending on environmental conditions.

Leucine

Leucine is located at position 14.

It has a hydrophobic branched side chain that contributes to the peptide's overall physicochemical properties.

Valine

Valine is the fifteenth and final residue in the commonly reported sequence.

Like leucine, valine has a hydrophobic branched side chain.

Its position at the carboxyl terminus forms part of the sequence identity.

No Cysteine Residues

The reported BPC-157 sequence does not contain cysteine.

Therefore, the unmodified sequence does not form conventional intramolecular disulfide bonds through cysteine residues.

This is a structural observation and should not be converted into a conclusion about biological behavior or product stability.

No Methionine Residues

The sequence also contains no methionine.

However, absence of methionine does not mean the peptide cannot undergo oxidative or other chemical changes because multiple degradation pathways can involve other residues or terminal groups.

Sequence Composition

The 15 positions contain:

  • 3 glycine residues
  • 1 glutamic-acid residue
  • 4 proline residues
  • 1 lysine residue
  • 2 alanine residues
  • 2 aspartic-acid residues
  • 1 leucine residue
  • 1 valine residue

This residue count describes the reference sequence, not a finished product composition.

Sequence and Molecular Formula

The commonly referenced peptide form is associated with the molecular formula:

C62H98N16O22

The formula is derived from the atoms present in the connected peptide structure.

A salt-associated or otherwise modified preparation can have a different complete material composition.

Sequence and Molecular Weight

The reported molecular weight is approximately 1419.5 g/mol for the reference peptide form.

Measured mass can be useful for identity confirmation, but mass alone may not distinguish every possible sequence-related species.

Why Mass Alone Is Not Complete Sequence Proof

Two different molecular arrangements can sometimes produce identical or nearly identical nominal masses.

Therefore, researchers may combine mass measurements with:

  • chromatographic separation
  • fragmentation analysis
  • sequence-specific methods
  • reference comparison

Orthogonal information strengthens identity characterization.

Sequence Confirmation by Mass Spectrometry

Mass spectrometry can provide information about:

  • intact molecular mass
  • fragment ions
  • sequence-related patterns
  • selected modifications
  • some impurity species

The exact interpretation depends on the instrument and analytical method.

Chromatographic Identity

Chromatography can help separate the intended peptide from related substances.

Variables include:

  • column chemistry
  • mobile phase
  • gradient
  • temperature
  • detection method

Retention time by itself is generally more informative when compared with suitable reference material and supporting identity data.

Sequence Variants

A sequence variant would contain one or more residue differences from GEPPPGKPADDAGLV.

Possible variants could arise through:

  • substitution
  • deletion
  • insertion
  • truncation
  • epimerization

A variant should not be described as identical BPC-157 without appropriate justification.

Deletion Sequences

During peptide synthesis, incomplete coupling can generate material missing one or more intended residues.

Such substances can sometimes be chemically similar to the target peptide and may require suitable chromatographic resolution.

Truncated Peptides

A truncated material contains only part of the full 15-residue sequence.

For example, loss of one or more terminal residues would produce a different molecular species.

The BPC-157 label should refer to the defined full sequence rather than an unspecified fragment.

Epimerized Residues

Peptide synthesis can potentially produce stereochemical variants under some conditions.

An epimerized residue may preserve nominal elemental composition while changing three-dimensional structure.

This illustrates why molecular weight alone cannot describe every aspect of identity.

Sequence and Salt Form Are Separate

The sequence GEPPPGKPADDAGLV defines the amino-acid order.

It does not specify whether a sample is associated with:

  • acetate
  • another counterion
  • residual synthesis-related acids
  • different quantities of associated water

These aspects require separate characterization.

Sequence and Purity Are Separate

A correct sequence and a purity percentage answer different questions.

A sample can contain the intended sequence together with:

  • sequence-related impurities
  • chemical degradation products
  • counterions
  • residual process materials
  • water

Sequence identity therefore does not establish overall sample purity.

Sequence and Quantity Are Separate

The sequence does not tell researchers how much BPC-157 is present in a container.

Quantity may be expressed as:

  • mass
  • moles
  • concentration
  • assay-corrected peptide amount

Each requires a separate measurement or documented calculation.

Sequence and Formulation Are Separate

A defined peptide can be incorporated into different research formulations.

Formulation variables may include:

  • buffer
  • pH
  • ionic strength
  • carrier
  • physical state
  • container

The sequence does not identify these variables.

Sequence and Route Are Separate

Nothing in GEPPPGKPADDAGLV specifies an injection, oral, nasal, topical, strip-based, or other route.

Route is an experimental or product characteristic rather than part of the amino-acid sequence.

Research findings should therefore identify the route separately.

Sequence Does Not Establish an Injectable Product

A peptide with the BPC-157 sequence is not automatically a finished injectable preparation.

An injectable preparation would require additional evaluation involving variables such as:

  • formulation
  • concentration
  • container
  • particulate matter
  • sterility
  • bacterial endotoxins

Those properties cannot be inferred from sequence identity.

Sequence Does Not Establish an Oral or Strip Product

Likewise, the peptide sequence alone does not define an oral product, peptide strip, tablet, capsule, or other dosage form.

Such preparations would require separate information about:

  • formulation composition
  • matrix materials
  • release conditions
  • stability
  • analytical recovery

The amino-acid sequence makes no statement about whether any such formulation is effective or suitable.

Sequence Does Not Establish Stability

The sequence can help researchers identify possible chemical vulnerabilities, but actual stability must be measured under defined conditions.

Variables may include:

  • temperature
  • pH
  • light
  • oxygen
  • buffer composition
  • surfaces
  • storage time

A literature description such as stable should remain connected to the conditions and methods under which stability was investigated.

Sequence Does Not Establish Protease Resistance

The presence of proline residues or another sequence feature does not by itself establish resistance to enzymatic degradation under every experimental condition.

Proteolysis studies require defined:

  • enzymes
  • concentrations
  • pH
  • temperature
  • incubation time
  • analytical method

Sequence-based predictions and measured degradation are separate evidence types.

Sequence Does Not Establish Biological Activity

A chemical sequence identifies a molecule. It does not establish a biological outcome.

Biological research must separately define:

  • the model
  • the preparation
  • experimental conditions
  • the measured endpoint
  • controls
  • limitations

Sequence Does Not Establish Effectiveness

Knowing the sequence does not demonstrate that a BPC-157 preparation produces a clinically meaningful result.

Effectiveness would be a separate evidence question involving a defined product, research design, comparator, population, and outcome.

Sequence Does Not Establish Safety

Similarly, a 15-residue sequence does not establish a general safety profile.

Safety-related interpretation can depend on:

  • the exact material
  • impurity profile
  • formulation
  • route
  • model
  • duration
  • quality of available evidence

Sequence Does Not Establish Product Identity

Even confirmation of GEPPPGKPADDAGLV does not completely identify a finished product.

Product-level information can include:

  • manufacturer
  • batch
  • counterion
  • purity
  • quantity
  • formulation
  • container
  • storage conditions

This distinction prevents molecular identity from being confused with product identity.

Why the Sequence Is Still Foundational

Although sequence does not answer every product question, it provides the molecular reference point for investigating:

  • identity
  • mass
  • related sequences
  • synthesis impurities
  • degradation
  • analytical specificity

Without the reference sequence, product comparisons become substantially less precise.

How to Report the Sequence in Research Writing

A concise description can state:

BPC-157 is a 15-residue peptide with the sequence GEPPPGKPADDAGLV.

Further description can then specify:

  • terminal form
  • counterion
  • manufacturer
  • purity method
  • formulation
  • research model

Relationship to BPC-157 Terminology

The sequence gives chemical meaning to a historical name that otherwise contains little structural information.

The origin and limitations of that nomenclature are explained in What Does the Name BPC-157 Mean?

Checking the Sequence Against an Authority Database

The PubChem BPC-157 compound record lists the sequence as GEPPPGKPADDAGLV and provides corresponding molecular-formula, molecular-weight, structural, and identifier information.

A database record is useful for reference identity, but it does not verify the identity, purity, formulation, or quality of a particular vial, commercial product, or research sample.

Final Perspective

The amino-acid sequence of BPC-157 is GEPPPGKPADDAGLV, corresponding to Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

This 15-residue sequence defines the core peptide identity and supports chemical and analytical comparison.

It does not identify the manufacturer, batch, salt form, purity, quantity, formulation, route, finished product, regulatory status, effectiveness, safety, or suitability for personal use. Accurate research coverage should keep the molecular sequence separate from those product-level and outcome-level questions.

Back to blog